The Curious Case of Eli Lilly’s Stock Pop and Other Pharmaceutical Wonders

by

Ah, Eli Lilly. The pharmaceutical giant that continually manages to pop up in the news like an overly ambitious balloon at a particularly high-stakes party. This time, the company’s stock shot up by a modest 3.2%, courtesy of a curious mix of news coming out of India and a slightly more cryptic set of opinions from Cantor Fitzgerald. Let’s dive in, shall we?

First, the *”good”* news (though “good” here might need quotation marks, as all good news in the stock market comes with a footnote). Eli Lilly, ever the savvy merchant of hope and profit, has decided to expand the Mounjaro GLP-1 weight loss drug business into India. A noble venture, no doubt-selling injector pens loaded with the weight loss elixir at the remarkably *modest* price of $160 for a 2.5 mg dose. (Of course, should you need a little more of this wonder drug, that price scales up-oh, yes, it does-up to $315 for the 15 mg dose. Don’t ask how much it costs to *lose* the weight of your soul in the process.)

Mounjaro: Entering the Indian Fray

Now, we have to admit, there’s something charmingly straightforward about this expansion. Lilly’s Mounjaro, you see, isn’t the only drug of its kind. No, no. It has competition-namely, Novo Nordisk’s Wegovy, which began its own Indian journey a few months back. To make things even more *enthralling*, Novo’s price tags for Wegovy range from $200 to $300, depending on whether you fancy a 0.25 mg or a 2.4 mg dose (because who wouldn’t want to pay more for less, am I right?).

Now, this is where the truly *fascinating* part lies. The dosages between the two drugs aren’t quite apples to apples. Oh, no. Mounjaro’s higher doses seem to provide the same weight loss results as Wegovy’s smaller amounts. So, naturally, Eli Lilly’s pricing strategy appears designed to tempt the Indian market with what could be seen as a rather *affordable* option-when, of course, you ignore the slightly tragic reality that any form of weight loss drug could arguably be priced at a level far below what it’s really worth in moral terms.

Loading widget...

What Cantor Fitzgerald Has to Say About Lilly

Ah, but the plot thickens! Today, we also received an update from Cantor Fitzgerald, a rather well-established name in the world of “you’ll buy anything if you squint hard enough.” Analyst Carter Gould, the voice of reason or perhaps the messenger of doom, has decided that while Lilly is still worth a look, it’s also worth a *discounted* price target of $825. So, you know, it’s not a *good* thing, but it’s not the worst thing either. There’s something magical about optimism in the face of lukewarm data.

Gould, being ever the beacon of optimism (or perhaps just the editor of a script we’ve all been forced to read), admitted that Lilly’s phase 3 trials for its orforglipron GLP-1 weight loss pill had underwhelmed. Yes, underwhelmed. That is to say, they were neither the glorious triumph of modern science nor the complete disaster one might expect after an industrial-scale push to shove a pill down the throats of the masses. A mere *meh*. Still, Gould assures us that this is a “show-me story”-as if the stock market is a play, and Eli Lilly is the lead actor, who has yet to fully convince the critics.

At a forward P/E ratio of 28 (which is, let’s face it, the financial equivalent of making a bold proclamation at a dinner party), and with a long-term projected earnings growth rate of 32%, it’s still hard to dismiss the stock outright. But, of course, one might ask-*is* that growth rate sustainable? And if it is, *for how long*?

In the end, the market, like a confused sorcerer, continues to throw its spells at stocks with the aim of transforming them into something magical. But, as anyone who’s tried to brew a potion knows, the results are not always as advertised. In the case of Eli Lilly, well… let’s just say that the stock might be worth buying, but it’s hardly the sure bet some might believe.

And thus, we are left to ponder the true nature of weight loss, pharma pricing, and the strange world of stock market spells. But, hey, as long as you’re not the one paying for it all, who can complain? 😉

Read More

2025-08-13 22:27